NCT04299880View on ClinicalTrials.gov

Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 24, 2020

Primary Completion Date

May 15, 2021

Study Completion Date

May 30, 2021

Conditions

Oncology

Interventions

DRUG

Napabucasin

Oral

DRUG

Nab-paclitaxel

Intravenous

DRUG

Gemcitabine

Intravenous

DRUG

Nivolumab

Intravenous

DRUG

Paclitaxel

Intravenous

DRUG

Irinotecan

Intravenous

DRUG

Leucovorin

Intravenous

DRUG

5Fluorouracil

Intravenous

DRUG

Bevacizumab

Intravenous

Trial Locations (7)

11217

Taipei Veterans General Hospital, Taipei

30322

Winship Cancer Institute, Emory University, Atlanta

97239

OHSU Knight Cancer Institute, Portland

04074

Maine Center for Cancer Medicine, Scarborough

06100

Centre Antoine Lacassagne, Nice

241-8515

Kanagawa Cancer Center, Yokohama

181-8611

Kyorin University Hospital, Tokyo

All Listed Sponsors

lead

Sumitomo Pharma America, Inc.

INDUSTRY

NCT04299880 - Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols | Biotech Hunter | Biotech Hunter